Examining the characteristics and beliefs of hydroxyurea users and nonusers among adults with sickle cell disease

American Journal of Hematology

Volumn 86, Issue 1, 2011, Pages 85-87

  Haywood, Carlton ^a,b   Beach, Mary Catherine ^a,b   Bediako, Shawn ^c   Carroll, C Patrick ^a   Lattimer, Lakshmi ^d   Jarrett, Dasheema ^e   Lanzkron, Sophie ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b JOHNS HOPKINS UNIVERSITY   (United States)

^c UNIVERSITY OF MARYLAND BALTIMORE COUNTY   (United States)

^d JOHNS HOPKINS HOSPITAL   (United States)

^e HOWARD UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HYDROXYUREA;

ADULT; CONTROLLED STUDY; DRUG EFFICACY; DRUG INFORMATION; FEMALE; HEALTH BELIEF; HUMAN; LETTER; MAJOR CLINICAL STUDY; MALE; PATIENT ATTITUDE; PRIORITY JOURNAL; SICKLE CELL ANEMIA;

ADULT; ANEMIA, SICKLE CELL; ANTISICKLING AGENTS; CROSS-SECTIONAL STUDIES; HUMANS; HYDROXYUREA; QUESTIONNAIRES; YOUNG ADULT;

EID: 78650376704     PISSN: 03618609     EISSN: 10968652     Source Type: Journal    
DOI: 10.1002/ajh.21883     Document Type: Letter

References (20)

1. Charache S, Terrin ML, Moore RD, et al. Effect of hydroxyurea on the frequency of painful crises in sickle cell anemia. Investigators of the multicenter study of hydroxyurea in sickle cell anemia. N Engl J Med 1995; 332: 1317-1322.
2. Moore RD, Charache S, Terrin ML, et al. Cost-effectiveness of hydroxyurea in sickle cell anemia. Investigators of the multicenter study of hydroxyurea in sickle cell anemia. Am J Hematol 2000; 64: 26-31.
3. Ballas SK, Barton FB, Waclawiw MA, et al. Hydroxyurea and sickle cell anemia: effect on quality of life. Health Qual Life Outcomes 2006; 4: 59.
4. Steinberg MH, Barton F, Castro O, et al. Effect of hydroxyurea on mortality and morbidity in adult sickle cell anemia: risks and benefits up to 9 years of treatment. JAMA 2003; 289: 1645-1651.
5. Steinberg MH, McCarthy WF, Castro O, et al. The risks and benefits of long-term use of hydroxyurea in sickle cell anemia: A 17.5 year follow-up. Am J Hematol 2010; 85: 403-408.
6. Carroll CP, Haywood CJr, Fagan P, Lanzkron S. The course and correlates of high hospital utilization in sickle cell disease: Evidence from a large, urban medicaid managed care organization. Am J Hematol 2009; 84: 666-670.
7. Kauf TL, Coates TD, Huazhi L, et al. The cost of health care for children and adults with sickle cell disease. Am J Hematol 2009; 84: 323-327.
8. Ballas SK. The cost of health care for patients with sickle cell disease. Am J Hematol 2009; 84: 320-322.
9. Kato GJ, Hebbel RP, Steinberg MH, Gladwin MT. Vasculopathy in sickle cell disease: Biology, pathophysiology, genetics, translational medicine, and new research directions. Am J Hematol 2009; 84: 618-625.
10. Olnes M, Chi A, Haney C, et al. Improvement in hemolysis and pulmonary arterial systolic pressure in adult patients with sickle cell disease during treatment with hydroxyurea. Am J Hematol 2009; 84: 530-532.
11. Strouse JJ, Lanzkron S, Beach MC, et al. Hydroxyurea for sickle cell disease: a systematic review for efficacy and toxicity in children. Pediatrics 2008; 122: 1332-1342.
12. Lanzkron S, Strouse JJ, Wilson R, et al. Systematic review: Hydroxyurea for the treatment of adults with sickle cell disease. Ann Intern Med 2008; 148: 939-955.
13. Haywood C, Jr, Beach MC, Lanzkron S, et al. A systematic review of barriers and interventions to improve appropriate use of therapies for sickle cell disease. J Natl Med Assoc 2009; 101: 1022-1033.
14. Brawley OW, Cornelius LJ, Edwards LR, et al. NIH consensus development statement on hydroxyurea treatment for sickle cell disease. NIH Consens State Sci Statements 2008; 25: 1-30.
15. Meyappan JD, Lampl M, Hsu LL. Parents' assessment of risk in sickle cell disease treatment with hydroxyurea. J Pediatr Hematol Oncol 2005; 27: 644-650.
16. Hankins J, Hinds P, Day S, et al. Therapy preference and decision-making among patients with severe sickle cell anemia and their families. Pediatr Blood Cancer 2007; 48: 705-710.
17. LaVista JM, Treise DM, Dunbar LN, et al. Development and evaluation of a patient empowerment video to promote hydroxyurea adoption in sickle cell disease. J Natl Med Assoc 2009; 101: 251-257.
18. Zumberg MS, Reddy S, Boyette RL, et al. Hydroxyurea therapy for sickle cell disease in community-based practices: A survey of Florida and North Carolina hematologists/oncologists. Am J Hematol 2005; 79: 107-113.
19. Lanzkron S, Haywood C, Jr, Hassell KL, Rand C. Provider barriers to hydroxyurea use in adults with sickle cell disease: A survey of the sickle cell disease adult provider network. J Natl Med Assoc 2008; 100: 968-973.
20. StataCorp. Stata statistical software: Release 10. StataCorp, 2007.